Navigation Links
EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
Date:7/14/2009

EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

London (PRWEB) July 14, 2009 -- EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

The Habib™ EndoHPB is an endoscopic bipolar radiofrequency (RF) catheter that allows for:

1) Destruction of biliary tumours prior to stent insertion: Currently, endoscopic plastic stents become clogged by sludge or by tumour pressure narrowing the stent lumen, necessitating regular changing of the stent. Use of the Habib™ EndoHPB prior to stent insertion improves the stent patency by delaying tumour growth.

2) Clearance of obstructed metal stents: Self-expanding mesh metal stents (SEMS), which have longer patency and lower occlusion rates, are still subject to obstructive tumour in-growth. Since SEMS cannot be removed, the Habib™ EndoHPB can be used to ablate the occluding tissue.

"The EndoHPB significantly improves on the procedure for patients suffering from malignant biliary obstruction," stated EMcision's CEO, the internationally renowned surgeon, Professor Nagy Habib. "I am particularly excited about the EndoHPB's application in clearing obstructed metal stents, which represents a real innovation. As a surgeon, I prefer simple and elegant systems and I believe we have achieved that with the EndoHPB. Interventional radiologists and endoscopists who use it tell us they like its convenience and efficacy, and administrators look kindly on the fact that no capital expenditure is required."

The Habib™ EndoHPB is inserted by the interventional radiologist in cases of hilar cholangiocarcinoma or by the endoscopist for tumours in the lower bile duct and head of pancreas. It is a sterile, single-use device compatible with the most commonly used RF generators. The fifth in EMcision's line of medical devices, the EndoHPB is CE marked and has earned considerable positive feedback from its use in clinical settings throughout Europe.

The Company's first product, the Habib™ 4X™, captured close to 30% share of the US hepatic resection market following its introduction under exclusive license to AngioDynamics (NASDAQ: ANGIO). "We expect similar success with the EndoHPB," stated Prof. Habib.

EMcision seeks U.S. distributors to help with this product rollout.

About EMcision:
Founded in 2001 to develop and commercialize clinically relevant and cost-effective medical devices which enhance the quality of patient care, EMcision Limited has introduced a series of innovative proprietary medical devices based on proven RF technology. EMcision's founder, Chairman and CEO Prof. Nagy Habib is also Chair of Surgery and Head of Liver and Pancreatic Surgery at Imperial College London and Hammersmith Hospital. The Company is backed by a group of investors, including the Imperial College University Challenge Seed Fund.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2634994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Xanodyne Announces New Executive Team Members
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
3. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
4. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
5. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... solutions for the food and pharmaceutical processing and packaging industries, was runner-up for ... manufacturer that has done the most or taken the most innovative steps to ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, an emerging ... dialysis, announced today that it has published the result of its recent research ... International (PDI), the official Journal of the International Society for Peritoneal Dialysis ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ... recent years, OHAUS Corporation ventured outside of weighing equipment with the goal of ... this vision in mind, the line of Starter water analysis meters were introduced ...
(Date:2/18/2017)... Research and Markets has announced the addition of the "Nanobiotechnology ... ... separate comprehensive analytics for the US, Japan , ... and forecasts are provided for the period 2015 through 2022. Also, ... and analytics are derived from primary and secondary research. This report ...
Breaking Biology Technology:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
Breaking Biology News(10 mins):